HCW Biologics Statistics
Total Valuation
HCW Biologics has a market cap or net worth of $7.38 million. The enterprise value is $12.72 million.
Important Dates
The last earnings date was Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HCW Biologics has 7.16 million shares outstanding. The number of shares has increased by 212.37% in one year.
| Current Share Class | 7.16M |
| Shares Outstanding | 7.16M |
| Shares Change (YoY) | +212.37% |
| Shares Change (QoQ) | +60.34% |
| Owned by Insiders (%) | 13.12% |
| Owned by Institutions (%) | 11.36% |
| Float | 6.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.12 |
| Forward PS | n/a |
| PB Ratio | 1.20 |
| P/TBV Ratio | 1.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.93 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.09, with a Debt / Equity ratio of 1.14.
| Current Ratio | 0.09 |
| Quick Ratio | 0.07 |
| Debt / Equity | 1.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.25 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -15.06% |
| Return on Invested Capital (ROIC) | -45.58% |
| Return on Capital Employed (ROCE) | -87.51% |
| Weighted Average Cost of Capital (WACC) | 12.64% |
| Revenue Per Employee | $188,348 |
| Profits Per Employee | -$517,652 |
| Employee Count | 35 |
| Asset Turnover | 0.25 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, HCW Biologics has paid $330,186 in taxes.
| Income Tax | 330,186 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.85% in the last 52 weeks. The beta is 2.21, so HCW Biologics's price volatility has been higher than the market average.
| Beta (5Y) | 2.21 |
| 52-Week Price Change | -76.85% |
| 50-Day Moving Average | 1.07 |
| 200-Day Moving Average | 1.77 |
| Relative Strength Index (RSI) | 42.42 |
| Average Volume (20 Days) | 1,336,149 |
Short Selling Information
The latest short interest is 417,960, so 5.84% of the outstanding shares have been sold short.
| Short Interest | 417,960 |
| Short Previous Month | 3.84M |
| Short % of Shares Out | 5.84% |
| Short % of Float | 6.72% |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, HCW Biologics had revenue of $6.59 million and -$18.12 million in losses. Loss per share was -$5.71.
| Revenue | 6.59M |
| Gross Profit | 6.54M |
| Operating Income | -6.46M |
| Pretax Income | -1.96M |
| Net Income | -18.12M |
| EBITDA | -5.70M |
| EBIT | -6.46M |
| Loss Per Share | -$5.71 |
Full Income StatementBalance Sheet
The company has $1.23 million in cash and $6.58 million in debt, giving a net cash position of -$5.35 million or -$0.75 per share.
| Cash & Cash Equivalents | 1.23M |
| Total Debt | 6.58M |
| Net Cash | -5.35M |
| Net Cash Per Share | -$0.75 |
| Equity (Book Value) | 5.76M |
| Book Value Per Share | 0.86 |
| Working Capital | -18.24M |
Full Balance SheetCash Flow
| Operating Cash Flow | -11.45M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 764,810 |
| Net Borrowing | -204,466 |
| Free Cash Flow | -11.45M |
| FCF Per Share | -$1.60 |
Full Cash Flow StatementMargins
Gross margin is 99.24%, with operating and profit margins of -98.01% and -34.74%.
| Gross Margin | 99.24% |
| Operating Margin | -98.01% |
| Pretax Margin | -29.73% |
| Profit Margin | -34.74% |
| EBITDA Margin | -86.41% |
| EBIT Margin | -98.01% |
| FCF Margin | n/a |
Dividends & Yields
HCW Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -212.37% |
| Shareholder Yield | -212.37% |
| Earnings Yield | -245.63% |
| FCF Yield | -155.27% |
Analyst Forecast
The average price target for HCW Biologics is $5.00, which is 385.44% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.00 |
| Price Target Difference | 385.44% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on April 11, 2025. It was a reverse split with a ratio of 1:40.
| Last Split Date | Apr 11, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
HCW Biologics has an Altman Z-Score of -6.52 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.52 |
| Piotroski F-Score | 4 |